Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Treatment of relapsed acute myelogeneous leukaemia with MLL/AF6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy

Leukemia volume 19, pages 1273–1274 (2005)Cite this article

TO THE EDITOR

In case of relapse of acute myelogeneous leukaemia (AML) after allogeneic blood stem cell transplantation (ABSCT), the treatment options are still very limited. In a recent issue of Leukemia, Schmid et al1 described an ingenious protocol of adoptive immunotherapy for the treatment of recurrent AML after ABSCT: low toxicity remission induction with cytarabine (Ara-C 2 × 10 mg/m2/day) was followed by a second peripheral blood stem cell (PBSC) transplantation from the same donor without conditioning and granulocyte–macrophage colony-stimulating factor (GM-CSF) for 4 weeks. In patients without signs of graft-versus-host disease (GvHD), interleukin-2 (IL-2) and donor lymphocyte infusion (DLI) were given afterwards. With this protocol in adults, a remission rate of 69% and a survival rate >6 months of 56% could be achieved.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Schmid C, Schleuning M, Aschan J, Ringden O, Hahn J, Holler E et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004; 18: 1430–1433.

    Article  CAS  Google Scholar 

  2. Creutzig U, Reinhardt D, Zimmermann M, AML-BFM Study Group. Prognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98. Ann Hematol 2004; 83 (Suppl 1): 112–116.

    Google Scholar 

  3. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ . Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–776.

    Article  CAS  Google Scholar 

  4. Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003; 9: 706–713.

    Article  Google Scholar 

  5. Woiciechowsky A, Regn S, Kolb HJ, Roskrow M . Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001; 15: 246–255.

    Article  CAS  Google Scholar 

  6. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996; 87: 1123–1133.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Competence network KPOH, Germany.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology and Oncology, Dr von Haunersches Kinderspital, Children Hospital of the Ludwig-Maximilians-University of Munich, Munich, Germany

    F R Schuster, M Führer & A Borkhardt

  2. Department of Pediatric Hematology and Oncology, University Children's Hospital, Gießen, Gießen, Germany

    W Woessmann, A Reiter, J Harbott & S Viehmann

Authors
  1. F R Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Führer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Woessmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Harbott
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Viehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Borkhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F R Schuster.

Additional information

Note added in proof

Recently, we measured an extremely low level of MLL/AF6 fusion ranging from 0.2 to 0.4 copies MLL/AF6 per 10 000 copies ABL mRNA in patient 2.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schuster, F., Führer, M., Woessmann, W. et al. Treatment of relapsed acute myelogeneous leukaemia with MLL/AF6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy. Leukemia 19, 1273–1274 (2005). https://doi.org/10.1038/sj.leu.2403791

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403791

Search

Advanced search

Quick links